The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects.

"Offering Zepbound single-dose vials…through another platform to LillyDirect will help ensure broader availability of ...

The biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag with tirzepatide for weight loss following ...

Tirzepatide has been shown in clinical trials to be more effective than diet and exercise support alone, and when compared ...

BioAge Labs has halted the Phase II randomised STRIDES trial of azelaprag,following the observation of liver transaminitis in some patients.

BioAge Labs’ stock lost more than two-thirds of its market cap in pre-market trading Monday, poised to hit an all-time low ...

The researchers emphasized ... Nov. 26, 2024 — Tirzepatide, a new injectable weight-loss drug, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three ...

Shares of BioAge Labs Inc. (BIOA) plummeted over 60% in after-hours trading on Friday, following the company's decision to ...

Data continue to show that tirzepatide, called Mounjaro for type 2 diabetes and Zepbound for weight loss, is safe and effective, but side effects remain.

Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.

The trial enrolled 751 adults with obesity or overweight conditions and at least one weight-related medical problem ...